Specialty Pharmacy

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, details the treatment options available for patients with congenital plasminogen deficiency.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, describes common manifestations of congenital plasminogen deficiency and their impact on patient outcomes.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses why congenital plasminogen deficiency is often underdiagnosed and describes the causes and characteristics of the disorder.

Anakinra was initially approved by FDA in November 2001 for treatment of moderate to severe active rheumatoid arthritis.

Without coordinated care to ensure proper adherence, the resulting costs can become downright staggering for health systems.

FDA approves margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens.

CAR T-cell therapy associated with greater anti-cancer activity in treating multiple myeloma.

The FDA has granted a fast track designation to devimistat (CPI-613) for the treatment of patients with acute myeloid leukemia.

Financial toxicity can lead to worse long-term outcomes and psychological distress among patients with breast cancer.

Rami Komrokji, MD, discusses whether the majority of patients in the MOST study were being treated at the time of enrollment, and why real-world data is so essential.

Study shows the mortality rate among breast cancer survivors is lower among those who received fertility preservation.

The cost of oncology treatment is high and rising in the United States.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about why data are limited in myelofibrosis.

For patients with relapsed/refractory multiple myeloma (RRMM), teclistamab was found to have a manageable safety profile, according to data presented at the virtual American Society of Hematology conference.

The data presented at ASH 2020 build on results previously observed in the pivotal HAVEN clinical trial among adults, adolescents, and children with hemophilia A, with and without factor VIII inhibitors.

Supreme Court decision establishes that states do have the right to regulate pharmacy benefit managers in managed care organizations.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about factors in treatment decisions for patients with myelofibrosis.

Data from a preliminary phase 1b/2 study demonstrated a single low-dose infusion of ciltacabtagene autoleucel resulted in early, deep, and durable responses in heavily pretreated patients with multiple myeloma.

MEDI2228, an ADC that targets the extracellular domain of human BCMA, demonstrated clinical efficacy at all dose levels in treating patients with relapsed/refractory multiple myeloma.

Trials confirm patients with chronic lymphocytic leukemia treated with venetoclax-based regimens achieve higher rates of undetectable minimal residual disease, which may be associated with a lower risk of future disease progression or death.

An icatibant injection has been released in the United States as an alternative treatment for acute attacks of hereditary angioedema in adults over the age of 18 years.

Although postoperative radiation therapy affected the risk of local recurrence of breast cancer, it did not significantly impact certain other clinical outcomes, including distant metastasis and recurrence in the opposite breast.

The higher risk of delivery and fetal complications suggests that physicians should more closely monitor pregnant breast cancer survivors.

Session at at the San Antonio Breast Cancer Symposium featured several abstract presentations on disparities in health care access in breast cancer, including research on the necessity of avoiding a one-size-fits-all approach to medicine.

Younger and Black patients are more likely to experience breast cancer symptom under-recognition.

Overdiagnosis of breast cancer can lead to unnecessarily aggressive treatments and mastectomies.

If current drug pricing trends continue, cost-related non-adherence to therapy will result in the premature deaths of 112,000 Medicare beneficiaries per year.

Grief can affect an organization as well as an individual; however, there are management strategies that can be used for addressing these issues.

There were significant modifications in breast cancer treatment due to the coronavirus disease 2019 pandemic, such as high rates of NET chemotherapy, genomic assay testing on core biopsies, and delays in planned surgeries.

Tesetaxel is a novel, oral taxane with several unique properties being investigated for use in patients with HER2-negative, HR-positive metastatic breast cancer.